Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Cash Flow (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Cash Flow for 16 consecutive years, with -$444000.0 as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 91.26% to -$444000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236000.0 through Dec 2025, up 101.51% year-over-year, with the annual reading at $236000.0 for FY2025, 101.51% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$444000.0 at Anika Therapeutics, down from $5.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $5.6 million in Q3 2023, with the low at -$14.7 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$1.9 million, with a median of -$1.3 million recorded in 2021.
  • The sharpest move saw Net Cash Flow plummeted 1433.3% in 2023, then soared 747.91% in 2025.
  • Over 5 years, Net Cash Flow stood at $3.3 million in 2021, then crashed by 141.95% to -$1.4 million in 2022, then soared by 254.96% to $2.1 million in 2023, then plummeted by 337.34% to -$5.1 million in 2024, then soared by 91.26% to -$444000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$444000.0, $5.1 million, and -$549000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.